UA105187C2 - Похідне 7-піперидиналкіл-3,4-дигідрохінолону - Google Patents
Похідне 7-піперидиналкіл-3,4-дигідрохінолонуInfo
- Publication number
- UA105187C2 UA105187C2 UAA201105428A UAA201105428A UA105187C2 UA 105187 C2 UA105187 C2 UA 105187C2 UA A201105428 A UAA201105428 A UA A201105428A UA A201105428 A UAA201105428 A UA A201105428A UA 105187 C2 UA105187 C2 UA 105187C2
- Authority
- UA
- Ukraine
- Prior art keywords
- disorder
- hydrate
- disorders
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 abstract 2
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010012218 Delirium Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Задача Створення нової сполуки, її фармацевтично прийнятної солі або гідрату для профілактики або лікування депресії, бентежності (наприклад, загального бентежного розладу, синдрому посттравматичного стресу, панічного синдрому, синдрому нав'язливої поведінки або страху публічних невдач), дефіциту уваги, манії, маніакально-депресивного психозу, шизофренії, розладів настрою, стресу, розладів сну, припадків, погіршення пам'яті, погіршення судження, слабоумства, амнезії, делірію, опасистості, розладів харчування, розладів апетиту, гіперфагії, булімії, патологічної відрази до їжі, діабету, серцево-судинних розладів, гіпертензії, дисліпідемії, інфаркту міокарда, розладів руху (наприклад, хвороби Паркінсона, епілепсії, судоми або дриґот), зловживання наркотиками, наркозалежності або статевих розладів, на основі дії антагоніста рецептора гормону, що концентрує меланін (рецептора МСН). Вирішення задачі Сполука, її фармацевтично прийнятна сіль або гідрат, представлені формулою (І). EMBED ISISServer
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008257072 | 2008-10-02 | ||
| PCT/JP2009/067441 WO2010038901A1 (en) | 2008-10-02 | 2009-09-30 | 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA105187C2 true UA105187C2 (uk) | 2014-04-25 |
Family
ID=42073652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201105428A UA105187C2 (uk) | 2008-10-02 | 2009-09-30 | Похідне 7-піперидиналкіл-3,4-дигідрохінолону |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8461182B2 (uk) |
| EP (1) | EP2344471B1 (uk) |
| JP (1) | JP5541279B2 (uk) |
| KR (1) | KR20110067026A (uk) |
| CN (1) | CN102239159B (uk) |
| AR (1) | AR073727A1 (uk) |
| AU (1) | AU2009300607C1 (uk) |
| BR (1) | BRPI0925343A2 (uk) |
| CA (1) | CA2739513A1 (uk) |
| CL (1) | CL2011000734A1 (uk) |
| CO (1) | CO6321164A2 (uk) |
| CY (1) | CY1114165T1 (uk) |
| DK (1) | DK2344471T3 (uk) |
| ES (1) | ES2424393T3 (uk) |
| HK (1) | HK1159622A1 (uk) |
| HR (1) | HRP20130728T1 (uk) |
| IL (1) | IL212070A (uk) |
| MX (1) | MX2011003500A (uk) |
| MY (1) | MY154337A (uk) |
| NZ (1) | NZ592008A (uk) |
| PE (1) | PE20110410A1 (uk) |
| PL (1) | PL2344471T3 (uk) |
| PT (1) | PT2344471E (uk) |
| RS (1) | RS52964B (uk) |
| RU (1) | RU2498981C2 (uk) |
| SI (1) | SI2344471T1 (uk) |
| UA (1) | UA105187C2 (uk) |
| WO (1) | WO2010038901A1 (uk) |
| ZA (1) | ZA201102315B (uk) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011219467A (ja) * | 2010-03-26 | 2011-11-04 | Taisho Pharmaceutical Co Ltd | ７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬 |
| US9512111B2 (en) | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
| EP2846804B1 (en) | 2012-05-08 | 2017-11-29 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| CA2872014A1 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
| KR101717872B1 (ko) | 2013-03-12 | 2017-03-17 | (주)바이오팜솔루션즈 | 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물 |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| CN106132422A (zh) | 2014-02-27 | 2016-11-16 | 莱斯拉公司 | 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法＆相关治疗方法 |
| AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
| EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
| EP3292119A4 (en) | 2015-05-05 | 2018-10-03 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
| MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
| CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
| WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| RU2018117503A (ru) | 2015-10-27 | 2019-11-28 | Мерк Шарп И Доум Корп. | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ |
| SI3413892T1 (sl) * | 2016-02-12 | 2022-06-30 | Cytokinetics, Incorporated | Tetrahidroizokinolinski derivati |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9610579A (pt) * | 1995-09-15 | 1999-07-06 | Sanofi Synthelabo | Derivados de quinolein-2(1H)-ona como antagonistas da serotonina |
| JP2005523237A (ja) | 2001-10-01 | 2005-08-04 | 大正製薬株式会社 | Ｍｃｈ受容体アンタゴニスト |
| WO2003035624A1 (fr) * | 2001-10-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Compose quinoline |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2004087680A1 (en) | 2003-03-31 | 2004-10-14 | Taisho Pharmaceutical Co., Ltd. | Novel quinazoline derivatives and methods of treatment related to the use thereof |
| US20050209274A1 (en) * | 2004-02-26 | 2005-09-22 | Lynch John K | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| NZ549673A (en) | 2004-03-30 | 2010-03-26 | Taisho Pharmaceutical Co Ltd | Pyrimidine derivatives and methods of treatment related to the use thereof |
| JP2008514546A (ja) | 2004-09-30 | 2008-05-08 | 大正製薬株式会社 | ピリジン誘導体及びその使用に関連する治療法 |
| WO2008044632A1 (fr) | 2006-10-06 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Dérivé de la 1-naphthyl alkylpipéridine |
-
2009
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Application Discontinuation
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en active Application Filing
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 RS RS20130370A patent/RS52964B/en unknown
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
-
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
-
2012
- 2012-01-04 HK HK12100046.0A patent/HK1159622A1/xx not_active IP Right Cessation
-
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown
- 2013-08-01 HR HRP20130728AT patent/HRP20130728T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA105187C2 (uk) | Похідне 7-піперидиналкіл-3,4-дигідрохінолону | |
| WO2005095357A3 (en) | Pyrimidine derivatives and methods of treatment related to the use thereof | |
| TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
| BRPI0408910A (pt) | composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica | |
| PL396873A1 (pl) | Sposób wytwarzania kompozycji | |
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| US9884854B2 (en) | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | |
| WO2005103039A8 (en) | 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists | |
| EP1685115A1 (en) | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | |
| GB2462235A (en) | NMDA and MC receptor antagonists exhibiting neuroprotective and memory enhancing activities | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| WO2004089308A3 (en) | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| NZ592563A (en) | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
| DK3059239T3 (en) | SULFUL, BICYCLIC RELATIONSHIP | |
| CN110997660A (zh) | 新型n-[(嘧啶基氨基)丙烷基]-、n-[(吡啶基氨基)丙烷基]-和n-[(吡嗪基氨基)丙烷基]芳基甲酰胺 | |
| MX2010008239A (es) | 2-aminoquinolinas. | |
| JP2008502653A5 (uk) | ||
| WO2002048105A3 (en) | Aryloxy piperidinyl derivatives for the treatment of depression | |
| US9073900B2 (en) | Dihydroquinone derivatives of piperidine and piperazine | |
| TH103570A (th) | 4-(แอริล-x-ฟีนิล)-1h-ไพริดิน-2-โอนซึ่งถูกแทนที่ที่ตำแหน่ง 1,3 |